Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Creighton University Janssen, LP |
---|---|
Information provided by: | Creighton University |
ClinicalTrials.gov Identifier: | NCT00208182 |
This medical study is an assessment of clinical response in women with Posttraumatic Stress Disorder (PTSD) due to domestic violence or rape trauma when treated with risperidone. Response to risperidone or placebo (inactive drug) is measured by Clinician Administered PTSD Scale (CAPS) and Treatment Outcomes PTSD Scale (TOP-8). Second, the effect of risperidone on depressive and anxiety symptoms will be assessed using the Hamilton Rating Scale for Anxiety, Hamilton Rating Scale for Depression and the Clinical Global Impression.
Condition | Intervention | Phase |
---|---|---|
Post-Traumatic Stress Disorder |
Drug: Risperidone |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial |
Estimated Enrollment: | 20 |
Study Start Date: | July 2001 |
Estimated Study Completion Date: | August 2004 |
Risperidone is an atypical antipsychotic that has been shown to be effective in both the core PTSD symptoms and psychotic symptoms associated with combat-induced PTSD in males. Case series have shown that risperidone is possibly effective in monotherapy or adjunctively in treating PTSD patients.
However, risperidone has never been tested in women with severe PTSD. Thus, we propose extending and expanding this research to another antipsychotic, risperidone, in a cohort of women who suffer PTSD as a consequence of domestic violence and/or rape trauma.
Ages Eligible for Study: | 19 Years to 64 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, Nebraska | |
Creighton University Psychiatry and Research Center | |
Omaha, Nebraska, United States, 68131 |
Principal Investigator: | Frederick Petty, MD, PhD | Creighton University |
Study ID Numbers: | RIS-USA-245B |
Study First Received: | September 13, 2005 |
Last Updated: | March 8, 2006 |
ClinicalTrials.gov Identifier: | NCT00208182 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Neurotransmitter Agents Tranquilizing Agents Wounds and Injuries Risperidone Psychotropic Drugs Stress Central Nervous System Depressants Antipsychotic Agents |
Stress Disorders, Traumatic Serotonin Dopamine Anxiety Disorders Mental Disorders Stress Disorders, Post-Traumatic Dopamine Agents |
Neurotransmitter Agents Tranquilizing Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Psychotropic Drugs Risperidone Central Nervous System Depressants Dopamine Antagonists Antipsychotic Agents Stress Disorders, Traumatic |
Pharmacologic Actions Serotonin Antagonists Serotonin Agents Anxiety Disorders Mental Disorders Therapeutic Uses Stress Disorders, Post-Traumatic Dopamine Agents Central Nervous System Agents |